Drawing up guidelines for the attendance of physical health of patients with severe mental illness;Élaboration de recommandations pour le suivi somatique des patients atteints de pathologie mentale sévère

Encephale

Volumn 35, Issue 4, 2009, Pages 330-339

  Saravane, D ^a   Feve, B ^b   Frances, Y ^c   Corruble, E ^b   Lancon, C ^d   Chanson, P ^b   Maison, P ^e   Terra, J L ^f   Azorin, J M ^d  

^a EPS de Ville Evrard   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL NORD   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CENTRE HOSPITALIER LE VINATIER   (France)

Author keywords

Antipsychotic drugs; Follow up; Metabolic and cardiovascular involvements; Pratical guidelines; Severe mental illness

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; HEALTH CARE DELIVERY; HEALTH PRACTITIONER; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY OF LIFE; RISK FACTOR; SMOKING HABIT; SOCIAL PSYCHOLOGY; BIPOLAR DISORDER; CAUSE OF DEATH; COOPERATION; DRUG INTERACTION; EDUCATION; FRANCE; HEALTH STATUS; INTERDISCIPLINARY COMMUNICATION; MAJOR DEPRESSION; PATIENT CARE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CAUSE OF DEATH; COMORBIDITY; COOPERATIVE BEHAVIOR; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; EDUCATION; FRANCE; HEALTH STATUS; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; RISK FACTORS; SCHIZOPHRENIA;

EID: 70349146653     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2008.10.014     Document Type: Article

References (27)

1. K.G. Alberti, P. Zimmet, and J. Shaw et al. The metabolic syndrome: a worldwide definition Lancet 366 2005 1059 1062
2. D.B. Allison, J.L. Mentore, and M. Heo et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696
3. American Diabetes Association, American Psychiatry Association, and American Association of Clinical Endocrinologists Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 7 2004 596 601
4. A.H. Barnett, P. Mackin, and I. Chaudhry et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity, and dyslipidaemia J Psychopharmacol 21 2007 357 373
5. S. Brown, H. Inskip, and B. Barraclough Causes of the excess of mortality in schizophrenia Br J Psychiatry 177 2000 12 17
6. F. Casadebaig, and A. Philippe Mortality in schizophrenic patients, 3 years follow-up of a cohort Encéphale 25 1999 329 337 (Pubitemid 29483485)
7. CSISG. Minimizing the risks associated with significant QT prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Austr Psychiatry 2002;10:115-24.
8. Covel NH, Jackson CT, & Weissman EM. Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai Conference recommendations. Postgrad Med 2006; spec. No 20-6.
9. M. De Hert, R. Van Winkel, and D. Van Eyck et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study Clin Pract Epidemol Ment Health 2 2006 14 17
10. De NayerA, M. De Hert, and A. Scheen et al. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics Int J Psychiatry Clin Pract 9 2005 130 137
11. A. Faglioni, E. Franck, and J.A. Scott et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Center for Pennsylvanians Bipolar Disord 7 2005 424 430
12. C. Gury, O. Canceil, and P. Iaria Antipsychotiques et sécurité cardiovasculaires : données actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires Encéphale XXVI 2000 62 72
13. P. Mackin, D.R. Bishop, and H.M.O. Watkinson A prospective study of monitoring practices for metabolic diseases in anti-psychotic treated community psychiatric patients BMC Psychiatry 7 2007 28 33
14. C. Montout, F. Casadebaig, and R. Lagnoui et al. Neuroleptics and mortality in schizophrenia : prospective analysis of deaths in a French cohort of schizophrenic patients Schizophren Res 57 2002 147 156
15. P.B. Mortensen, and K. Juel Mortality and causes of death in first admitted schizophrenic patients Br J Psychiatry 163 1993 183 189
16. S. Mukherjee, D.B. Schnur, and R. Reddy Family history of type 2 diabetes in schizophrenic patients Lancet 8636 1989 495
17. H. Nasrallah, J. Mc Evoy, and J. Meyer Low rate of treatment for metabolic disorders in the CATIE schizophrenia trial at baseline: healthcare disparities in schizophrenia Paper presented at ACNP 44th Annual Meeting 2005; December 11-15 2005
18. J.W. Newcomer Metabolic considerations in the use of antipsychotic medications: a review of recent evidence J Clin Pschiatry 68 2007 S20 S27
19. M.J. Poulin, L. Cortese, and R. Williams Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring Can J Psychiatry 50 2005 555 562
20. J.G. Reilly, S.A. Avis, and I.N. Ferrier et al. QTC-interval abnormalities and psychiatric drug therapy in psychiatric patients The Lancet 355 2000 1048 1052
21. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30.
22. M.C. Ryan, and J.H. Thakore Physical consequences of schizophrenia and its treatment: the metabolic syndrome Life Sci 71 2002 239 257
23. M.C. Ryan, P. Collins, and J.H. Thakore Impaired fasting glucose tolerance in first episode, drug-naïve patients with schizophrenia Am J Psychatry 160 2003 284 289
24. R. Schulz, S.R. Beach, and D.G. Ives et al. Association between depression and mortality in older adults: the Cardiovascular Health Study Arch Int Med 160 2000 1761 1768
25. M. Srisurapanont, S. Likhitsathian, and V. Boonyanaruthee et al. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one year follow-up study BMC Psychiatry 7 2007 14 17
26. P. Toalson, S. Ahmed, and T. Hardy et al. The metabolic syndrome in patients with severe mental illness Prim Care Companion J Clin Psychiatry 6 2004 152 158
27. V. Woo, S.B. Harris, and R.L. Houden Canadian Association position paper: antipsychotic medications and associated risks of weight gain and diabetes Can J Diab 29 2005 111 112